Answers are grounded in this paper and cite their sources.
Importance Metformin has known metabolic effects and associated survival benefits in head and neck cancer. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) also modulate systemic metabolism through regulating blood glucose levels and lipid metabolism. Objective To investigate whether GLP-1RAs are associated with survival outcomes in patients with head and neck cancers. Design, Setting, and Participants This retrospective cohort study was conducted using clinical data from January 1, 1990, through December 1, 2025, from the TriNetX Global Collaborative Network. Adults with histologically confirmed head and neck squamous cell carcinomas (HNSCC) were included. Data were analyzed in January 2026. Main Outcomes and Measures The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1RAs and metformin. Adjusted hazard ratios (aHRs) with 95% CIs were estimated. Results There were 4532 patients (mean [SD] age, 63.4 [10.9] years; 1638 female individuals [36.1%] and 2891 male individuals [63.8%]) included in the cohort. Across all subsites, GLP-1RA users had significantly improved overall survival compared with controls at 1-year (aHR, 0.42; 95% CI, 0.36-0.49), 3-year (aHR, 0.48; 95% CI, 0.43-0.54), and 5-year intervals (aHR, 0.51; 95% CI, 0.46-0.57). By anatomic subsite, GLP-1RA use remained consistently associated with a lower hazard of mortality at 5-year intervals (oral cavity: aHR, 0.60; 95% CI, 0.51-0.70; oropharynx: aHR, 0.51; 95% CI, 0.41-0.64; larynx: aHR, 0.49; 95% CI, 0.39-0.61). We also observed significant overall survival among patients who used GLP-1RAs and metformin at 1 year (aHR, 0.29; 95% CI, 0.23-0.36), 3 years (aHR, 0.36; 95% CI, 0.30-0.42) and 5 years (aHR, 0.39; 95% CI, 0.34-0.45). Conclusions The findings of this cohort study suggest that there may be survival benefits associated with GLP-1RA use among patients with HNSCC across several subsites. Future prospective and interventional studies of GLP-1RA potential metabolic adjuncts in oncologic care may help corroborate the associations from this retrospective study.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: